IDEXX Laboratories, Inc. (NASDAQ:IDXX) Given Consensus Rating of “Moderate Buy” by Analysts

Posted by George Bondi on May 15th, 2026

IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Free Report) has received an average recommendation of “Moderate Buy” from the eleven research firms that are presently covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $751.00.

IDXX has been the subject of several analyst reports. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday. Stifel Nicolaus dropped their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. UBS Group dropped their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Finally, Barclays dropped their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th.

Read Our Latest Stock Analysis on IDXX

Insiders Place Their Bets

In other news, EVP Michael G. Erickson sold 5,371 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the completion of the transaction, the executive vice president directly owned 12,693 shares in the company, valued at approximately $7,963,334.34. This represents a 29.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total value of $15,338,011.30. Following the transaction, the chief executive officer owned 83,606 shares of the company’s stock, valued at approximately $54,975,125.30. This represents a 21.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 34,612 shares of company stock valued at $22,525,070. 0.79% of the stock is owned by company insiders.

Hedge Funds Weigh In On IDEXX Laboratories

Hedge funds have recently made changes to their positions in the stock. SHP Wealth Management purchased a new position in shares of IDEXX Laboratories during the 4th quarter worth approximately $26,000. Virtus Advisers LLC purchased a new position in shares of IDEXX Laboratories during the 3rd quarter worth approximately $26,000. Park Place Capital Corp purchased a new position in shares of IDEXX Laboratories during the 4th quarter worth approximately $29,000. WealthCollab LLC purchased a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $30,000. Finally, J.Safra Asset Management Corp purchased a new position in shares of IDEXX Laboratories during the 3rd quarter worth approximately $31,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 0.8%

Shares of NASDAQ IDXX opened at $532.86 on Friday. IDEXX Laboratories has a 12-month low of $496.61 and a 12-month high of $769.98. The stock has a market cap of $42.03 billion, a PE ratio of 39.24, a P/E/G ratio of 3.08 and a beta of 1.58. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The company has a 50-day moving average of $574.48 and a 200 day moving average of $646.38.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the business earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts predict that IDEXX Laboratories will post 14.66 EPS for the current fiscal year.

About IDEXX Laboratories

(Get Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Analyst Recommendations for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.